Functionalized dendrimer-based delivery of angiotensin type 1 receptor siRNA for preserving cardiac function following infarction

Biomaterials

Volumn 34, Issue 14, 2013, Pages 3729-3736

  Liu, Jie ^a,b   Gu, Catherine ^b   Cabigas, E Bernadette ^b   Pendergrass, Karl D ^b   Brown, Milton E ^b   Luo, Ying ^a,b   Davis, Michael E ^a,b,c  

^a PEKING UNIVERSITY   (China)

^b Emory University   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiomyocyte; Dendrimer; Gene expression; Ischemia reperfusion

Indexed keywords

CARDIAC FUNCTIONS; CARDIOMYOCYTES; CARDIOVASCULAR DISEASE; DELIVERY SYSTEMS; INFLAMMATORY GENES; ISCHEMIA REPERFUSION; RNA INTERFERENCE; SALINE INJECTION;

AMINO ACIDS; GENE EXPRESSION; GENETIC ENGINEERING; RNA;

DENDRIMERS;

ANGIOTENSIN 1 RECEPTOR; DENDRIMER; SMALL INTERFERING RNA; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE SILENCING; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART PROTECTION; IN VITRO STUDY; IN VIVO CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; REPERFUSION INJURY; SYNTHESIS; TADPOLE;

ANIMALS; CELLS, CULTURED; DENDRIMERS; MALE; MYOCARDIAL INFARCTION; RANDOM ALLOCATION; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, SMALL INTERFERING;

RATTUS;

EID: 84875262973     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.02.008     Document Type: Article

References (45)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics-2012 update a report from the American Heart Association. Circulation 2012, 125:E2-E220.
2. Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991, 121:1244-1263.
3. Dzau V.J., Antman E.M., Black H.R., Hayes D.L., Manson J.E., Plutzky J., et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006, 114:2850-2870.
4. Probstfield J.L., O'Brien K.D. Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am J Cardiol 2010, 105:10A-20A.
5. Dzau V.J. Theodore Cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001, 37:1047-1052.
6. Ferrario C.M., Strawn W.B. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006, 98:121-128.
7. Ma T.K., Kam K.K., Yan B.P., Lam Y.Y. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 2010, 160:1273-1292.
8. Harada K., Sugaya T., Murakami K., Yazaki Y., Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 1999, 100:2093-2099.
9. Yang Z., Bove C.M., French B.A., Epstein F.H., Berr S.S., DiMaria J.M., et al. Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. Circulation 2002, 106:106-111.
10. Kaschina E., Grzesiak A., Li J., Foryst-Ludwig A., Timm M., Rompe F., et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?. Circulation 2008, 118:2523-2532.
11. Ichihara S., Senbonmatsu T., Price E., Ichiki T., Gaffney F.A., Inagami T. Targeted deletion of angiotensin II type 2 receptor caused cardiac rupture after acute myocardial infarction. Circulation 2002, 106:2244-2249.
12. Oishi Y., Ozono R., Yoshizumi M., Akishita M., Horiuchi M., Oshima T. AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling. Life Sci 2006, 80:82-88.
13. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
14. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
15. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875-886.
16. Berthonneche Corinne, Sulpice Thierry, Tanguy Stéphane, O'Connor Stephen, Herbert Jean-Marc, Janiak Philippe, et al. AT1 receptor blockade prevents cardiac dysfunction and remodeling and limits TNF-α generation early after myocardial infarction in rats. Cardiovasc Drugs Ther 2005, 19:251-259.
17. Daniels M.C., Keller R.S., de Tombe P.P. Losartan prevents contractile dysfunction in rat myocardium after left ventricular myocardial infarction. Am J Physiol Heart Circ Physiol 2001, 281:H2150-H2158.
18. Yang B.C., Phillips M.I., Zhang Y.C., Kimura B., Shen L.P., Mehta P., et al. Critical role of AT1 receptor expression after ischemia/reperfusion in isolated rat hearts: beneficial effect of antisense oligodeoxynucleotides directed at AT1 receptor mRNA. Circ Res 1998, 83:552-559.
19. Voros S., Yang Z., Bove C.M., Gilson W.D., Epstein F.H., French B.A., et al. Interaction between AT1 and AT2 receptors during postinfarction left ventricular remodeling. Am J Physiol Heart Circ Physiol 2006, 290:H1004-H1010.
20. Nam H.Y., Kim J.S., Kim S.W., Bull D.A. Cell targeting peptide conjugation to siRNA polyplexes for effective gene silencing in cardiomyocytes. Mol Pharmacol 2012, 9:1302-1309.
21. Nam H.Y., Kim J., Kim S., Yockman J.W., Kim S.W., Bull D.A. Cell penetrating peptide conjugated bioreducible polymer for siRNA delivery. Biomaterials 2011, 32:5213-5222.
22. Nam H.Y., McGinn A., Kim P.H., Kim S.W., Bull D.A. Primary cardiomyocyte-targeted bioreducible polymer for efficient gene delivery to the myocardium. Biomaterials 2010, 31:8081-8087.
23. Lau S., Graham B., Cao N., Boyd B.J., Pouton C.W., White P.J. Enhanced extravasation, stability and in vivo cardiac gene silencing via in situ siRNA-albumin conjugation. Mol Pharmacol 2012, 9:71-80.
24. Kesharwani P., Gajbhiye V., Jain N.K. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012, 33:7138-7150.
25. Gray W.D., Che P.L., Brown M., Ning X.H., Murthy N., Davis M.E. N-acetylglucosamine conjugated to nanoparticles enhances myocyte uptake and improves delivery of a small molecule p38 inhibitor for post-infarct healing. J Cardiovasc Transl Res 2011, 4:631-643.
26. Xu Q.X., Wang C.H., Pack D.W. Polymeric carriers for gene delivery: chitosan and poly(amidoamine) dendrimers. Curr Pharm Des 2010, 16:2350-2368.
27. Stasko N.A., Johnson C.B., Schoenfisch M.H., Johnson T.A., Holmuhamedov E.L. Cytotoxicity of polypropylenimine dendrimer conjugates on cultured endothelial cells. Biomacromolecules 2007, 8:3853-3859.
28. Mukherjee S.P., Davoren M., Byrne H.J. In vitro mammalian cytotoxicological study of PAMAM dendrimers - towards quantitative structure activity relationships. Toxicol In Vitro 2010, 24:169-177.
29. Jain K., Kesharwani P., Gupta U., Jain N.K. Dendrimer toxicity: let's meet the challenge. Int J Pharm 2010, 394:122-142.
30. Hunter A.C. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv Drug Deliv Rev 2006, 58:1523-1531.
31. Liu J., Gray W.D., Davis M.E., Luo Y. Peptide- and saccharide-conjugated dendrimers for targeted drug delivery: a concise review. Interface Focus 2012, 2:307-324.
32. Waite C.L., Sparks S.M., Uhrich K.E., Roth C.M. Acetylation of PAMAM dendrimers for cellular delivery of siRNA. BMC Biotechnol 2009, 9:38-47.
33. Won Y.W., McGinn A.N., Lee M., Bull D.A., Kim S.W. Targeted gene delivery to ischemic myocardium by homing peptide-guided polymeric carrier. Mol Pharmacol 2012, 10:278-285.
34. Ko Y.T., Hartner W.C., Kale A., Torchilin V.P. Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide. Gene Ther 2009, 16:52-59.
35. Cigola E., Kajstura J., Li B., Meggs L.G., Anversa P. Angiotensin II activates programmed myocyte cell death in vitro. Exp Cell Res 1997, 231:363-371.
36. Grishko V., Pastukh V., Solodushko V., Gillespie M., Azuma J., Schaffer S. Apoptotic cascade initiated by angiotensin II in neonatal cardiomyocytes: role of DNA damage. Am J Physiol Heart Circ Physiol 2003, 285:H2364-H2372.
37. Flynn J.D., Akers W.S. Effects of the angiotensin II subtype 1 receptor antagonist losartan on functional recovery of isolated rat hearts undergoing global myocardial ischemia-reperfusion. Pharmacotherapy 2003, 23:1401-1410.
38. Jalowy A., Schulz R., Dorge H., Behrends M., Heusch G. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 1998, 32:1787-1796.
39. Jugdutt B.I., Menon V. AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction. Mol Cell Biochem 2004, 260:111-118.
40. Jugdutt B.I., Menon V. Upregulation of angiotensin II type 2 receptor and limitation of myocardial stunning by angiotensin II type 1 receptor blockers during reperfused myocardial infarction in the rat. J Cardiovasc Pharmacol Ther 2003, 8:217-226.
41. Nio Y., Matsubara H., Murasawa S., Kanasaki M., Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 1995, 95:46-54.
42. Horio T., Nishikimi T., Yoshihara F., Matsuo H., Takishita S., Kangawa K. Effects of adrenomedullin on cultured rat cardiac myocytes and fibroblasts. Eur J Pharmacol 1999, 382:1-9.
43. Porrello E.R., Mahmoud A.I., Simpson E., Johnson B.A., Grinsfelder D., Canseco D., et al. Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family. Proc Natl Acad Sci U S A 2013, 110:187-192.
44. Eulalio A., Mano M., Dal Ferro M., Zentilin L., Sinagra G., Zacchigna S., et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature 2012, 492:376-381.
45. Jayawardena T.M., Egemnazarov B., Finch E.A., Zhang L., Payne J.A., Pandya K., et al. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res 2012, 110:1465-1473.